Last edition
News about "Phase 3 GlucoGene study"
FDA Grants Accelerated Approval to Ultragenyx's Genglycos for Rare GSDIa
Gene therapy becomes the first treatment designed to directly address the underlying cause of glycogen storage disease type Ia in patients aged eight and older.
Phase 3 GlucoGene Study | 21/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members